Achilles Therapeutics PLC ACHL:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/16/21 EDT
15.15UNCH (UNCH)
Volume
203
Close
15.15quote price arrow up+0.55 (+3.77%)
Volume
37,147
52 week range
12.63 - 18.95

...

Loading . . .
  • Open14.60
  • Day High15.15
  • Day Low14.15
  • Prev Close14.60
  • 52 Week High18.95
  • 52 Week High Date03/31/21
  • 52 Week Low12.63
  • 52 Week Low Date04/12/21

Key Stats

  • Market Cap615.39M
  • Shares Out40.62M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

KEY STATS

  • Open14.60
  • Day High15.15
  • Day Low14.15
  • Prev Close14.60
  • 52 Week High18.95
  • 52 Week High Date03/31/21
  • 52 Week Low12.63
  • 52 Week Low Date04/12/21
  • Market Cap615.39M
  • Shares Out40.62M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.79
  • P/E (TTM)-8.46
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-32.955M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Achilles Therapeutics PLC

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Achilles Therapeutics plc is a clinical stage immuno-oncology biopharmaceutical company that is engaged in developing precision T cell therapies to treat multiple types of solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT)....
Address
245 Hammersmith Road
London
W6 8PW
United Kingdom